Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasms 1Melanoma 1Glioblastoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

tremelimumab 4Ipilimumab 4lenvatinib 3durvalumab 3Nivolumab 3pembrolizumab 2balstilimab 2Pemetrexed 2Carboplatin 2Bevacizumab 2spartalizumab 1relatlimab 1poly ICLC 1osimertinib 1cemiplimab 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Standard of Care 1Platinum 1Peptides 1Paclitaxel 1Opdualag 1Docetaxel 1Capecitabine 1Blood Specimen Collection 1Axitinib 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Peptides × 1 year × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡